EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aridis Pharmaceuticals's enterprise value is $7.44 Mil.
Aridis Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $19.65 Mil. Therefore, Aridis Pharmaceuticals's EV-to-Revenue for today is 0.38.
The historical rank and industry rank for Aridis Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
ARDS'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1.73 Med: 44.05 Max: 2440.66
Current: 0.38
During the past 7 years, the highest EV-to-Revenue of Aridis Pharmaceuticals was 2440.66. The lowest was -1.73. And the median was 44.05.
ARDS's EV-to-Revenue is ranked better than 91.23% of 1038
companies
in the Biotechnology industry
Industry Median: 8.075
vs ARDS: 0.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aridis Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Aridis Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aridis Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aridis Pharmaceuticals's EV-to-Revenue falls into.
Aridis Pharmaceuticals's current Enterprise Value is $7.44 Mil.
Aridis Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals's share price for today is $0.0525.
Aridis Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aridis Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aridis Pharmaceuticals (Aridis Pharmaceuticals) Business Description
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARDS has been successfully added to your 